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Abstract
Background and Aims: Although the advent of ultra-deep sequencing technology allows for the analysis of heretofore-
undetectable minor viral mutants, a limited amount of information is currently available regarding the clinical implications
of hepatitis B virus (HBV) genomic heterogeneity.
Methods: To characterize the HBV genetic heterogeneity in association with anti-viral therapy, we performed ultra-deep
sequencing of full-genome HBV in the liver and serum of 19 patients with chronic viral infection, including 14 therapy-naı ¨ve
and 5 nucleos(t)ide analogue(NA)-treated cases.
Results: Most genomic changes observed in viral variants were single base substitutions and were widely distributed
throughout the HBV genome. Four of eight (50%) chronic therapy-naı ¨ve HBeAg-negative patients showed a relatively low
prevalence of the G1896A pre-core (pre-C) mutant in the liver tissues, suggesting that other mutations were involved in
their HBeAg seroconversion. Interestingly, liver tissues in 4 of 5 (80%) of the chronic NA-treated anti-HBe-positive cases had
extremely low levels of the G1896A pre-C mutant (0.0%, 0.0%, 0.1%, and 1.1%), suggesting the high sensitivity of the
G1896A pre-C mutant to NA. Moreover, various abundances of clones resistant to NA were common in both the liver and
serum of treatment-naı ¨ve patients, and the proportion of M204VI mutants resistant to lamivudine and entecavir expanded
in response to entecavir treatment in the serum of 35.7% (5/14) of patients, suggesting the putative risk of developing drug
resistance to NA.
Conclusion: Our findings illustrate the strong advantage of deep sequencing on viral genome as a tool for dissecting the
pathophysiology of HBV infection.
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Introduction
Hepatitis B virus (HBV) is a non-cytopathic DNA virus that
infects approximately 350 million people worldwide and is a main
cause of liver-related morbidity and mortality [1–3]. The absence
of viral-encoded RNA-dependent DNA polymerase proofreading
capacity coupled with the extremely high rate of HBV replication
yields the potential to rapidly generate mutations at each
nucleotide position within the entire genome [4]. Accordingly, a
highly characteristic nature of HBV infection is the remarkable
genetic heterogeneity at the inter- and intra- patient level. The
latter case of variability as a population of closely-related but
nonidentical genomes is referred to as viral quasispecies [5,6]. It is
well recognized that such mutations may have important
implications regarding the pathogenesis of viral disease. For
example, in chronic infection, G to A point mutation at nucleotide
(nt) 1896 in the pre-core (pre-C) region as well as A1762T and
G1764A mutations in the core-promoter region are highly
associated with HBeAg seroconversion that in general results in
the low levels of viremia and consequent clinical cure [7–9]. In
contrast, acute infection with the G1896A pre-C mutant
represents a high risk for fulminant hepatic failure [10,11].
Although these facts clearly illustrate the clinical implications of
certain viral mutation, increasing evidence strongly suggests that
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35052the viral genetic heterogeneity is more complicated than previously
thought [12,13].
The major goals of antiviral therapy in patients with HBV
infection areto prevent the progression of liver disease and inhibit the
development of hepatocellular carcinoma [14]. Oral nucleos(t)ide
analogue (NA) have revolutionized the management of HBV
infection, and five such antiviral drugs, including lamivudine,
adefovir,entecavir,tenofovir, and telbivudine,are currently approved
medications [15,16]. These agents are well-tolerated, very effective at
suppressing viral replication, and safe, but one of the major problems
of NA therapy is that long-term use of these drugs frequently causes
the emergence of antiviral drug-resistant HBV due to substitutions at
specific sites in the viral genome sequences, which often negates the
benefits of therapy and is associated with hepatitis flares and death
[16,17]. It is unclear whether viral clones with antiviral resistance
emerge after the administration of antiviral therapy or widely preexist
among treatment-naı ¨ve patients.
There has been a recent advance in DNA sequencing
technology [18]. The ultra-deep sequencers allow for massively
parallel amplification and detection of sequences of hundreds of
thousands of individual molecules. We recently demonstrated the
usefulness of ultra-deep sequencing technology to unveil the
massive genetic heterogeneity of hepatitis C virus (HCV) in
association with treatment response to antiviral therapy [19]. On
the other hand, there are a few published studies in which this
technology was used to characterize genetic HBV sequence
variations [20–22]. Margeridon-Thermet et al reported that the
454 Life Science GS20 sequencing platform provided higher
sensitivity for detecting drug-resistant HBV mutations in the serum
of patients treated with nucleoside and nucleotide reverse-
transcriptase inhibitors [20]. Solmone et al also reported the
strong advantage conferred by the same platform to detect minor
variants in the serum of patients with chronic HBV infection [21].
Although in these previous studies low-abundant drug-resistant
variants were successfully detected, the analyses were focused on
the reverse-transcriptase region of circulating HBV in the serum
and thus the whole picture of HBV genetic heterogeneity as well as
the in vivo dynamics of HBV drug resistant variants in response to
anti-viral treatment remains to be clarified. Moreover, intrahe-
patic viral heterogeneity in patients that achieved the clearance of
circulating HBV is largely unknown.
By taking the advantage of an abundance of genetic information
obtained by utilizing the Illumina Genome Analyzer II (Illumina,
San Diego, CA) as a platform of ultra-deep sequencing, we
determined the whole HBV sequence in the liver and serum of
patients with chronic HBV infection to evaluate viral quasispecies
characteristics. Moreover, we investigated the prevalence of rare
drug-resistant HBV variants as well as detailed dynamic changes
in the viral genetic heterogeneity in association with NA
administration. Based on the abundant genetic information
obtained by ultra-deep sequencing, we clarified the precise
prevalence of HBV clones with G1896A pre-C mutations in
association with HBe serostatus in chronically infected patients
with or without NA treatment. We also detected a variety of minor
drug-resistant clones in treatment-naı ¨ve patients and their
dynamic changes in response to entecavir administration,
demonstrating the potential clinical significance of naturally-
occurring drug-resistant mutations.
Materials and Methods
Ethics Statement
The Kyoto University ethics committee approved the study, and
written informed consent for participation in this study was
obtained from all patients. The study was conducted in
accordance with the principles of the Declaration of Helsinki.
Patients
The liver tissues of 19 Japanese patients that underwent living-
donor liver transplantation at Kyoto University due to HBV-
related liver disease were available for viral genome analyses.
These individuals included 13 men and 6 women, aged 41 to 69
years (median, 55.2 years) and all but one were infected with
genotype C viruses. Participants comprised 19 patients with liver
cirrhosis caused by chronic HBV infection, including 14 antiviral
therapy-naı ¨ve cases (chronic-naı ¨ve cases) and 5 cases receiving NA
treatment, with either lamivudine or entecavir (chronic-NA cases)
(Table 1). Serum HBV DNA levels were significantly higher in
chronic-naı ¨ve cases than in chronic NA cases (median serum HBV
DNA levels were 5.6, and ,2.6 log copies/ml, respectively,
Table 1). Liver tissue samples were obtained at the time of
transplantation, frozen immediately, and stored at 280uC until
use. Serologic analyses of HBV markers, including hepatitis B
surface antigen (HBsAg), antibodies to HBsAg, anti-HBc, HBeAg,
and antibodies to HBeAg, were determined by enzyme immuno-
assay kits as described previously [23]. HBV DNA in the serum
before transplantation was examined using a polymerase chain
reaction (PCR) assay (Amplicor HBV Monitor, Roche, Branch-
burg, NJ). To examine the dynamics of viral quasispecies in
response to anti-HBV therapy, paired serum samples of 14
treatment-naı ¨ve patients before and after administration of daily
entecavir (0.5 mg/day) were subjected to further analyses on viral
genome.
Direct population Sanger sequencing
DNA was extracted from the liver tissue and serum using a
DNeasy Blood & Tissue Kit (Qiagen, Tokyo, Japan). To define the
consensus reference sequences of HBV in each clinical specimen,
all samples were first subjected to direct population Sanger
sequencing using the Applied Biosystems 3500 Genetic Analyzer
(Applied Biosystems, Foster City, CA). Oligonucleotide primers for
the HBV genome were designed to specifically amplify whole viral
sequences as two overlapping fragments using the sense primer
169_F and antisense primer 2847_R to yield a 2679-bp amplicon
(amplicon 1), and the sense primer 685_F and antisense primer
443_R to yield a 2974-bp amplicon (amplicon 2; Table S1). HBV
sequences were amplified using Phusion High-Fidelity DNA
polymerase (FINZYMES, Espoo, Finland). All amplified PCR
products were purified using the QIAquick Gel Extraction kit
(Qiagen) after agarose gel electrophoresis and used for direct
sequencing. The serum of a healthy HBV DNA-negative volunteer
was used as a negative control.
Viral genome sequencing by massively-parallel
sequencing
Massively-parallel sequencing with multiplexed tags was
performed using the Illumina Genome Analyzer II as described
[19]. The end-repair of DNA fragments, addition of adenine to the
39 ends of DNA fragments, adaptor ligation, and PCR
amplification by Illumina PCR primers were performed as
described previously [24]. Briefly, the viral genome sequences
were amplified by high-fidelity PCR using oligonucleotide primers
as described above, sheared by nebulization using 32 psi N2 for
8 min, and then the sheared fragments were purified and
concentrated using a QIAquick PCR purification Kit (Qiagen).
Nucleotide overhangs resulting from fragmentation were then
converted into blunt ends using T4 DNA polymerase and Klenow
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adaptor containing unique 6-bp tags, such as ‘‘ATCACG’’ and
‘‘CGATGT’’ (Multiplexing Sample Preparation Oligonucleotide
Kit, Illumina), was then ligated to each fragment using DNA
ligase. We then performed agarose gel electrophoresis of adaptor-
ligated DNAs and excised bands from the gel to produce libraries
with insert sizes ranging from 200 to 350 bp. These libraries were
amplified independently using a minimal PCR amplification step
of 18 cycles by Illumina PCR primers with Phusion High-Fidelity
DNA polymerase. The DNA fragments were then purified with a
MinElute PCR Purification Kit (Qiagen), followed by quantifica-
tion using the NanoDrop 2000C (Thermo Fisher Scientific,
Waltham, MA) to make a working concentration of 10 nM.
Cluster generation and sequencing was performed for 64 cycles on
the Illumina Genome Analyzer II according to the manufacturer’s
instructions. The obtained images were analyzed and base-called
using GA pipeline software version 1.4 with the default settings
provided by Illumina.
Genome Analyzer sequence data analysis
Using the high performance alignment software ‘‘NextGene‘‘
(SoftGenetics, State College, PA), the 64 base-pair reads obtained
from the Genome Analyzer II were aligned with the reference
sequences of 3215 bp that were determined by direct population
Sanger sequencing of each clinical specimen. Reads with 90% or
more bases matching a particular position of the reference
sequences were aligned. Furthermore, two quality filters were
used for sequencing reads: the reads with a median quality score of
more than 30 and no more than 3 uncalled nucleotides were
allowed anywhere in the 64 bases. Only sequences that passed the
quality filters, rather than raw sequences, were analyzed and each
position of the viral genome was assigned a coverage depth,
representing the number of times the nucleotide position was
sequenced.
Allele-specific quantitative real-time PCR and
semiquantitative PCR to determine the relative
proportion of G1896A pre-C mutant
To determine the relative proportion of the G1896A pre-C
mutant, allele-specific quantitative real-time PCR was performed
based on the previously described method [25,26]. Oligonucleo-
tide primers were designed individually to amplify the pre-C
region of wild-type and the G1896A pre-C mutant HBV. Three
primers were used for this protocol, two allele-specific sense
primers, 1896WT_F (for wild-type) and 1896MT_F (for the
G1896A pre-C mutant), and one common antisense primer,
2037_R (Table S1). Quantification of wild-type and the G1896A
pre-C mutant was individually performed by real-time PCR using
a Light Cycler 480 and Fast Start Universal SYBR Master (Roche,
Mannheim, Germany) [27]. The relative proportion of the
G1896A pre-C mutant was determined to calculate the G1896A
pre-C mutant/total HBV ratios. Performance of this assay was
tested using mixtures of two previously described plasmids,
pcDNA3-HBV-wt#1 and pcDNA3-HBV-G1896A pre-C mutant
[28]. Semiquantitative PCR was performed using primers
described above, then agarose gel electrophoresis was performed.
Statistical analysis
Results are expressed as mean or median, and range.
Pretreatment values were compared using the Mann-Whitney
U-test or the Kruskal Wallis H-test. P values less than 0.05 were
considered statistically significant.
The viral quasispecies characteristics were evaluated by
analyzing the genetic complexity based on the number of different
sequences present in the population. Genetic complexity for each
site was determined by calculating the Shannon entropy using the
following formula:
Sn~{
Pn
i~1 fi(lnfi)
N
Table 1. Characteristics of patients with chronic HBV infection analyzed in this study.
Chronic-naı ¨ve (N=14) Chronic-NA (N=5)
Age
{ 55.5 (41–69) 55.0 (49–68)
Sex (male/female) 9/5 4/1
Alanine aminotransaminase (IU/l)
{ 41 (10–74) 30 (15–65)
Total bilirubin (mg/dl)
{ 0.9 (0.5–31.1) 1.7 (0.6–4.5)
Platelet count (610
4/mm
3)
{ 12.7 (3.3–27.6) 5.1 (3.6–11.3)
HBV genotype
B1 0
C1 3 5
Viral load (log copies /ml)
{ 5.6 (,2.6–8.8)* ,2.6 (,2.6–5.3)*
HBe-serostatus (HBeAg+/HBeAb+) 8/6 0/5
Fibrosis
F0–F2 6 0
F3–F4 8 5
Activity
A0–A1 7 3
A2–A3 7 2
{Values are median (range).
*P=0.042.
doi:10.1371/journal.pone.0035052.t001
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observed frequency of a particular variant in the quasispecies, and
N is the total number of clones analyzed [12,13]. The mean viral
complexity in each sample was determined by calculating the total
amounts of the Shannon entropy at each nucleotide position
divided by the total nucleotide number (e.g., 3215 bases) of each
HBV genome sequence.
Nucleotide sequence accession number
All sequence reads have been deposit in DNA Data Bank of
Japan Sequence Read Archive (http://www.ddbj.nig.ac.jp/index-
e.html) under accession number DRA000435.
Results
Validation of multiplex ultra-deep sequencing of the HBV
genome
To differentiate true mutations from sequencing errors in the
determined sequences, we first generated viral sequence data from
the expression plasmid, pcDNA3-HBV-wt#1, encoding wild-type
genotype C HBV genome sequences [28]. For this purpose, we
determined the PCR-amplified HBV sequences derived from the
expression plasmid using high-fidelity Taq polymerase to take the
PCR-induced errors as well as sequencing errors into consider-
ation. Viral sequences determined by the conventional Sanger
method were used as reference sequences for aligning the
amplicons obtained by ultra-deep sequencing. Three repeated
ultra-deep sequencing generated a mean of 77,663 filtered reads,
corresponding to a mean coverage of 38,234 fold at each
nucleotide site (Table S2). Errors comprised insertions
(0.00003%), deletions (0.00135%), and nucleotide mismatches
(0.037%). The mean overall error rate was 0.034% (distribution of
per-nucleotide error rate ranged from 0 to 0.13%) for the three
control experiments, reflecting the error introduced by high-
fidelity PCR amplification and by multiplex ultra-deep sequencing
that remained after filtering out problematic sequences. We also
confirmed that multiplex ultra-deep sequencing with and without
the high-fidelity PCR amplification with HBV-specific primer sets
showed no significant differences in the error rates on the viral
sequence data (mean error rate 0.034% vs 0.043%). Accordingly,
we defined the cut-off value in its current platform as 0.3%, a
value nearly 1 log above the mean overall error rate.
Next, we performed additional control experiments to verify the
detectability of the low abundant mutations that presented at a
frequency of less than 0.3%. For this purpose, we introduced
expression plasmids with a single-point mutation within that
encoding a wild-type viral sequence with a ratio of 1:1000 and
assessed the sensitivity and accuracy of quantification using high-
fidelity PCR amplification followed by multiplex ultra-deep
sequencing in association with the different coverage numbers
(Table S3). Repeated control experiments revealed that the
threshold for detecting low-abundant mutations at an input ratio
of 0.10% among the wild-type sequences ranged between 0.11%
and 0.24%, indicating that there was no significant difference in
the detection rate or error rates under the different coverage
conditions. Based on these results, the accuracy of ultra-deep
sequencing in its current platform for detecting low-level viral
mutations was considered to be greater than 0.30%.
Viral complexity of the HBV quasispecies in association
with clinical status
To clarify HBV quasispecies in association with clinical status,
we performed multiplex ultra-deep sequencing and determined
the HBV full-genome sequences in the liver and serum with
chronic HBV infection. First, we compared the sequences of the
viral genome determined in the liver tissue with those in the serum
and found no significant differences in the viral population
between the liver and serum of the same individual. Indeed, the
pattern and distribution of genetic heterogeneity of the viral
nucleotide sequences in the liver tissue were similar to those
observed in the serum of the same patient (Figure S1), suggesting
that a similar pattern of viral heterogeneity was maintained in the
liver and serum of patients with chronic HBV infection.
Next, we compared the viral heterogeneity in the liver of
chronic-naı ¨ve and chronic-NA cases. A mean of 5,962,996 bp
nucleotides in chronic-naı ¨ve cases and 4,866,783 bp nucleotides in
chronic-NA cases were mapped onto the reference sequences, and
an overall average coverage depth of 1,855 and 1.514 was
achieved for each nucleotide site of the HBV sequences,
respectively (Table 2). The frequencies of mutated positions and
altered sequence variations detected in each viral genomic region
are summarized in Table 2. The overall mutation frequency of the
total viral genomic sequences was determined to be 0.87% in
chronic-naı ¨ve cases and 0.69% in chronic-NA cases. Most
genomic changes observed in viral variants were single base
substitutions, and the genetic heterogeneity of the viral nucleotide
sequences was equally observed throughout the individual viral
genetic regions, including the pre-surface (preS), S, pre-core,core
(preC-C), and X (Table 2). Consistent with the findings obtained
from the viral mutation analyses, the overall viral complexity
determined by the Shannon entropy value was 0.047 in chronic-
naı ¨ve and 0.036 in chronic-NA cases, and the viral complexity was
equally observed throughout the individual viral genetic region
(Figure 1A). Among chronic-naı ¨ve cases, we observed no
significant differences in the viral complexity in HBV DNA level,
age, or degree of fibrosis (Figure 1B).
High sensitivity of the G1896A pre-C mutant to
nucleos(t)ide analogues
Emergence of G1896A mutation in the pre-C region, and
A1762T and G1764A mutations in the core-promoter region is
well known to be associated with HBe-seroconversion [7–9]. We
then evaluated the prevalence of these three mutations in the
chronically HBV-infected liver, in association with HBe serologic
status and the NA treatment history. In chronic-naive cases, 6 and
8 patients showed the pre- and post- HBeAg seroconversion status,
respectively (Table 3). The mean prevalence of the G1896A pre-C
mutant in HBeAg-positive cases was lower than that in the
HBeAg-negative cases (27.4% and 46.5%, respectively). Impor-
tantly, however, 4 of 8 HBeAg-negative cases showed a relatively
low prevalence of the G1896A pre-C mutant (Liver #8, #12,
#13, #14), and all but one case (Liver #10) showed a high
prevalence of the A1762T and G1764A mutations, irrespective of
HBe serologic status and NA treatment history (Table 3). These
findings suggested that other mutations except G1896A, A1762T
and G1764A were also involved in the HBeAg seroconversion
status. Notably, liver tissues of all but one (Liver #17) chronic-NA
cases showed extremely low levels of the G1896A pre-C mutant
(0.0, 0.0, 0.1, and 1.1%), suggesting the high sensitivity of the
G1896A pre-C mutant to NA (Table 3).
To confirm the difference of the sensitivity to NA between the
wild-type and the G1896A pre-C mutant, we examined the
dynamic changes of the relative proportion of the G1896A pre-C
mutant in the serum of 14 treatment-naı ¨ve patients before and
after entecavir administration. Consistent with the findings
obtained by ultra-deep sequencing, quantitative real-time PCR
revealed that entecavir administration significantly reduced the
proportion of the G1896A pre-C mutant in 13 of 14 cases (92.9%)
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mutant were detectable in substantial proportion before treatment
in all cases (Figure 2A, 2B and 2C; p=0.001). These results further
support the findings that HBV clones comprising the G1896A
mutation were more sensitive to NA than those with wild-type
sequences.
Prevalence of drug-resistant HBV clones in the liver of
treatment-naı ¨ve patients
Increasing evidence suggests that drug-resistant viral mutants
can be detected in the serum of treatment-naı ¨ve patients with
chronic HBV infection [20,21]. Thus, we next determined the
actual prevalence of spontaneously-developed drug-resistant
mutants in chronically-infected liver of treatment-naı ¨ve patients
to evaluate whether NA treatment potentiates the expansion of
drug-resistant clones. The drug-resistant mutations examined
included two mutations resistant to lamivudine and entecavir,
four mutations resistant to entecavir, and three mutations resistant
to adefovir [16,17]. Based on the detection rate of the low-level
viral clones determined by the control experiments, we identified
the drug-resistant mutants present in each specimen at a frequency
of more than 0.3% among the total viral clones. Based on these
criteria, at least one resistant mutation was detected in the liver of
all of the chronic-naı ¨ve cases with chronic HBV infection (Table 4).
Figure 1. Viral complexity of the HBV quasispecies in association with clinical status. (A) The Shannon entropy values for each viral
genomic region were determined in the liver of chronic-naı ¨ve and chronic-NA cases. (B) Among the chronic-naı ¨ve cases, the Shannon entropy values
are shown for patients with serum HBV DNA levels less than 5.0 log copies/ml (,5.0) and greater than 5.0 log copies/ml ($5.0) (left panel), patients
under the age of 55 years (,55) and over the age of 55 ($55) (middle panel), and patients with low (F1–2) and high (F3–4) liver fibrosis levels (right
panel). preS: pre-surface, preC-C: precore,core N.S.: not significant.
doi:10.1371/journal.pone.0035052.g001
Table 2. The frequency of mutation rate and the Shannon
entropy in each viral genome region.
Liver
Chronic-naı ¨ve (N=14) Chronic-NA (N=5)
Average aligned reads 93,172 76,043
Average aligned nucleotides 5,962,996 4,866,783
Average coverage 1,855 1,514
Mutation rate (%)
Overall 0.87 0.69
preS 0.92 0.81
S 0.96 0.71
preC-C 1.05 0.72
X 0.63 0.61
Shannon entropy 0.047 0.036
Mutation rate (%): the ratio of total different nucleotides from the reference
sequence to total aligned nucleotides.
preS: pre-surface, preC-C: pre-core,core.
doi:10.1371/journal.pone.0035052.t002
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deep sequencing in 14 chronic-naı ¨ve cases ranged from 0.3% to
30.0%, indicating that the proportion of resistant mutations
substantially differed in each case. The most commonly detected
mutation was M204VI (9 cases) and M250VI (11 cases), which
were resistant to lamivudine and entecavir, and entecavir,
respectively. Other mutations resistant to adefovir were detected
in 7 (50.0%) and 3 (21.4%) cases at A181TV and N236T,
respectively (Table 4).
Nine (64.2%) chronic-naı ¨ve cases possessed the M204VI
mutants in their liver tissues and the proportion of mutant clones
among the totally infected viruses ranged from 0.3% to 1.1%
among the M204VI mutant-positive patients. In chronic-NA
cases, 4 of 5 (80.0%) liver tissues harbored the M204VI mutants
with the proportion among the totally infected viruses ranging
from 0.4% to 18.7% (Table 4), while the mean serum HBV DNA
was suppressed below 2.6 log copies/ml (Table 1). These results
suggest that the mutant HBV clones comprising various drug-
resistant mutations could latently exist even in the liver of NA
treatment-naı ¨ve cases.
Expansion of drug-resistant HBV clones harboring
M240VI mutations in response to NA administration
To clarify the risk of latent expansion of drug-resistant
mutations due to NA treatment, we next examined the early
dynamic changes of the prevalence of M204VI mutants in the
serum of treatment-naı ¨ve patients in response to entecavir
treatment. Ultra-deep sequencing provided a mean 40,791- and
38,823-fold coverage of readings, which were mapped to the
M204VI nucleotide position at the YMDD sites of each reference
sequence in patients before and after entecavir treatment.
Five of 14 (35.7%) patients harbored the M204VI mutations
prior to entecavir treatment. Although the serum HBV DNA
levels were significantly reduced in response to entecavir in all
cases, the M204VI mutant clones were detected in 9 cases
(64.3%) after entecavir administration (Table 5). Notably, one
patient (Serum #3) who harbored the M240VI mutant clones at
baseline had a relatively large expansion of drug-resistant clones
among the total viral population in a time-dependent manner in
response to entecavir treatment (Table 5). Similarly, M240VI
mutant clones became detectable after entecavir administration
in four patients (Serum #1, #7, #12, #13) that harbored no
resistant mutants at baseline (Table 5). We found no correlation
between the degree of the increase in the relative prevalence of
M204VI mutant clones and that of the reduction in serum HBV
DNA levels. Although only a limited number of patients exhibited
a substantial increase in M204VI mutant clones after adminis-
tration of anti-viral therapy, our findings might suggest that
entecavir treatment latently causes selective survival of drug-
resistant mutants in treatment naı ¨ve patients with chronic HBV
infection.
Table 3. The prevalence of G1896A mutation in the pre-C region, and A1762T and G1764A mutations in the core-promoter region
in the liver of patients chronically infected with HBV.
Mutation Frequency
HBeAg/HBeAb
NA (duration of
treatment) G1896A (Pre C) A1762T (CP) G1764A (CP)
Chronic-naive
Liver #1 +/2 - 640/1652 (38.7) 1647/1941 (84.9) 1683/1979 (85.0)
Liver #2 +/2 - 9/596 (1.5) 682/687 (99.3) 683/689 (99.1)
Liver #3 +/2 - 273/672 (40.6) 767/769 (99.7) 757/760 (99.6)
Liver #4 +/2 - 204/701 (29.1) 610/625 (97.6) 602/621 (96.9)
Liver #5 +/2 - 27/152 (17.8) 249/250 (99.6) 245/248 (98.8)
Liver #6 +/2 - 228/621 (36.7) 727/729 (99.7) 743/744 (99.9)
Liver #7 2/+ - 740/1193 (62.0) 1908/1913 (99.7) 1888/1913 (98.7)
Liver #8 2/+ - 111/1892 (5.9) 2321/2325 (99.8) 2335/2339 (99.8)
Liver #9 2/+ - 10935/10944 (99.9) 12019/12032 (99.9) 12163/12170 (99.9)
Liver #10 2/+ - 4554/4593 (99.2) 1/5191 (0) 4/5188 (0.1)
Liver #11 2/+ - 811/921 (88.1) 1234/1236 (99.8) 1226/1228 (99.8)
Liver #12 2/+ - 93/1265 (7.4) 1234/1234 (100) 1228/1229 (99.9)
Liver #13 2/+ - 83/877 (9.5) 1465/1529 (95.8) 1485/1549 (95.9)
Liver #14 2/+ - 0/717 (0) 1078/1410 (76.5) 1089/1414 (77.0)
Chronic-NA
Liver #15 2/+ LAM (156w) 0/390 (0) 441/453 (97.4) 435/448 (97.1)
Liver #16 2/+ ETV (1w) 0/1399 (0) 1624/1632 (99.5) 1625/1630 (99.7)
Liver #17 2/+ LAM (144w) 345/816 (42.3) 988/991 (99.7) 994/994 (100)
Liver #18 2/+ LAM (98w) 2/3963 (0.1) 1015/1188 (85.4) 1190/1194 (99.7)
Liver #19 2/+ LAM (11w) 48/4214 (1.1) 3438/3456 (99.5) 3446/3462 (99.5)
Values in parenthesis show mutation frequency (%): the ratio of total mutant clones to total aligned coverage at each nucleotide sites.
NA: nucleotide analogue, pre C: precore, CP: core promoter, LAM: lamivudine, ETV: entecavir.
doi:10.1371/journal.pone.0035052.t003
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Direct population sequencing is the most common method for
detecting viral mutations [29]. Conventional sequencing tech-
niques, however, are not efficient for evaluating large amounts of
genetic information of the viruses. Newly developed ultra-deep
sequencing technology have revolutionized genomic analyses,
allowing for studies of the dynamics of viral quasispecies as well as
rare genetic variants of the viruses that cannot be detected using
standard direct population sequencing techniques [30,31]. The
sensitivity of ultra-deep sequencing analysis is primarily limited by
errors introduced during PCR amplification and the sequencing
reaction, thus it is a challenge to distinguish rare variants from
sequencing artifacts. In the present study, we optimized the ultra-
deep sequencing with a multiplex-tagging method and reproduc-
ibly detected variants within HBV quasispecies that were as rare as
0.3%. Based on this ultra-deep sequencing platform, we
determined the abundant genetic heterogeneity of HBV at the
intra- and inter-individual levels.
Because of its ability to handle abundant viral genome
information, ultra-deep sequencing allowed us to evaluate low-
abundant virus variants of patients with chronic HBV infection in
detail. It is widely accepted that HBe seroconversion is highly
associated with the emergence of G1896A pre-C and/or A1762T
and G1764A core promoter mutant clones [7–9]. Unexpectedly,
however, our results showed a diverse range of G1896A frequency
(0–99.9%) in HBeAg-negative subjects and a high prevalence of
core promoter mutations, irrespective of HBe serostatus. Consis-
tent with our observation, previous studies utilizing conventional
sequencing methods reported that the frequency of the G1896A
pre-C mutant ranged from 12% to 85% [32]. All but one patient
(Liver #10) showing a predominance of A1762T and G1764A
were infected with genotype C, while patient#10 was infected
with genotype B. Because A1762T and G1764A are reported to be
significantly more frequent in genotype C [33], the difference in
the prevalence of A1762T and G1764A in our study might be a
reflection of the viral HBV genotype rather than HBe serostatus.
Further investigation of the actual prevalence of these mutations
Figure 2. The reduction in the relative proportion of the G1896A pre-C mutant clones after entecavir administration. (A) The relative
proportion of the G1896A pre-C mutant was determined in the serum of treatment-naı ¨ve patients pre- and post-entecavir administration using
quantitative real-time PCR. Serum #1,6 were HBeAg-negative and HBeAb-positive, and Serum #7,14 were HBeAg-positive and HBeAb-negative
before treatment. *: p,0.05 (B) Semiquantitative PCR analysis was performed using primers specific to the wild-type (upper panel) or G1896A pre-C
mutant (lower panel) pre- and post-entecavir administration. A representative result from 5 cases is shown. (C) The relative proportion of the G1896A
pre-C mutant was compared in 14 treatment-naı ¨ve patients between pre- and post-entecavir administration.
doi:10.1371/journal.pone.0035052.g002
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M204V/I L180M T184S/A/I/ L/G/C/M S202C/G/I I169T
Drugs LAM/ETV LAM/ETV ETV ETV ETV
Chronic-naive
Liver #1 27/5421 (0.5%) 2/3694 (-) 9/3886 (-) 5/5613 (-) 5/3784 (-)
Liver #2 35/5344 (0.7%) 0/538 (-) 1/563 (-) 17/6340 (-) 0/512 (-)
Liver #3 13/1363 (1.0%) 0/304 (-) 1/358 (-) 1/1379 (-) 0/264 (-)
Liver #4 11/5113 (-) 0/556 (-) 2/547 (0.4%) 11/5133 (-) 0/639 (-)
Liver #5 2/117 (1.1%) 0/409 (-) 1/380 (-) 1/189 (-) 1/474 (-)
Liver #6 12/8451 (-) 0/309 (-) 0/328 (-) 22/8457 (-) 0/334 (-)
Liver #7 10/3098 (0.3%) 1/1547 (-) 3/1477 (-) 8/3161 (-) 0/1621 (-)
Liver #8 13/2442 (0.5%) 1/2378 (-) 6/2312 (-) 1/2564 (-) 1/2507 (-)
Liver #9 67/13879 (0.5%) 2/5443 (-) 2/5107 (-) 6/13804 (-) 0/5650 (-)
Liver #10 16/7400 (-) 0/3524 (-) 3/3283 (-) 5/7113 (-) 0/3492 (-)
Liver #11 0/412 (-) 1/1328 (-) 1/295 (0.3%) 0/425 (-) 3/4729 (-)
Liver #12 4/1098 (0.4%) 1/1389 (-) 0/1272 (-) 2/1102 (-) 0/1544 (-)
Liver #13 8/2476 (0.3%) 1/2192 (-) 3/2085 (-) 4/2529 (-) 4/5029 (-)
Liver #14 5/3713 (-) 0/2009 (-) 4/1925 (-) 2/3820 (-) 5/3784 (-)
Chronic-NA
Liver #15 0/339 (-) 0/49 (-) 0/49 (-) 0/338 (-) 0/40 (-)
Liver #16 28/7278 (0.4%) 0/4403 (-) 6/4053 (-) 14/7556 (-) 6/6084 (-)
Liver #17 177/945 (18.7%) 0/1059 (-) 0/1009 (-) 0/945 (-) 0/1051 (-)
Liver #18 13/2655 (0.5%) 0/1239 (-) 0/1185 (-) 10/2708 (0.4%) 0/1332 (-)
Liver #19 80/6795 (1.2%) 0/3168 (-) 2/2971 (-) 3/6734 (-) 0/3384 (-)
M250V/I A181T/V N236T P237H
Drugs ETV ADV ADV ADV
Chronic-naive
Liver #1 23/2719 (0.9%) 10/3755 (-) 4/4210 (-) 2/4139 (-)
Liver #2 9/2079 (0.4%) 2/549 (0.4%) 1/1144 (-) 1/1188 (-)
Liver #3 10/1699 (0.6%) 1/298 (0.3%) 3/1636 (-) 1/1666 (-)
Liver #4 3/388 (0.8%) 3/549 (0.5%) 0/560 (-) 0/533 (-)
Liver #5 2/91 (2.2%) 1/409 (-) 0/55 (-) 0/60 (-)
Liver #6 0/214 (-) 6/305 (2.0%) 1/294 (0.3%) 0/257 (-)
Liver #7 7/1289 (0.5%) 4/1531 (-) 24/2738 (0.9%) 1/2692 (-)
Liver #8 2/1117 (-) 689/2336 (29.5%) 2/1713 (-) 0/1639 (-)
Liver #9 27/7325 (0.4%) 38/5334 (0.7%) 1/6607 (-) 4/6702 (-)
Liver #10 12/3815 (0.3%) 0/3454 (-) 13/3245 (0.4%) 2/3272 (-)
Liver #11 1/199 (0.5%) 1/972 (-) 0/251 (-) 0/251 (-)
Liver #12 2/672 (0.3%) 408/1362 (30.0%) 0/598 (-) 0/597 (-)
Liver #13 1/947 (-) 2/2160 (-) 0/1406 (-) 1/1374 (-)
Liver #14 23/2719 (0.9%) 10/3755 (-) 4/4210 (-) 2/4139 (-)
Chronic-NA
Liver #15 1/303 (0.3%) 2/49 (4.1%) 0/377 (-) 0/384 (-)
Liver #16 1/922 (-) 0/4403 (-) 1/1597 (-) 3/1572 (-)
Liver #17 0/755 (-) 1/1050 (-) 0/698 (-) 145/698 (20.8%)
Liver #18 1/1464 (-) 2/1206 (-) 0/3156 (-) 0/3107 (-)
Liver #19 8/3834 (-) 16/3128 (0.5%) 0/3372 (-) 0/3428 (-)
(-): mutant clones less than 0.3% among total clones at each nucleotide sites.
LAM: lamivudine, ADV: adefovir, ETV: entecavir.
doi:10.1371/journal.pone.0035052.t004
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seroconversion are necessary for a better understanding of the
underlying mechanisms of HBe seroconversion.
One thing to be noted is that the majority of the chronic-NA
cases had extremely low levels of the G1896A pre-C mutant in
their liver tissues, even though those cases were serologically
positive for anti-HBe and negative for HBeAg. Moreover,
entecavir administration significantly reduced the proportion of
the G1896A pre-C mutant in the serum of the majority of patients
irrespective of their HBeAg serostatus, while the G1896A pre-C
mutant clones were detectable in a substantial proportion before
treatment in all cases. These findings suggest that the G1896A pre-
C mutant have higher sensitivity to NA than the wild-type viruses.
Consistent with this hypothesis, several previous studies reported
that NA is effective against acute or fulminant hepatitis caused by
possible infection with the G1896A pre-C mutant [34,35]. Based
on these findings, early administration of NA might be an effective
strategy for treating patients with active hepatitis infected
predominantly with the G1896A pre-C mutant.
Ultra-deep sequencing has a relatively higher sensitivity than
conventional direct population sequencing and is thus useful for
detecting drug-resistant mutations not detected by standard
sequencing [20,21]. Recently, we revealed that drug-resistant
mutants were widely present in treatment-naı ¨ve HCV-infected
patients, suggesting a putative risk for the expansion of resistant
clones to anti-viral therapy [19]. Here, we demonstrated that
various drug-resistant HBV variants are present in a proportion of
chronically HBV-infected, NA-naı ¨ve patients. Several studies
using ultra-deep sequencing provided evidence that naturally-
occurring drug-resistant mutations are detectable in treatment-
naı ¨ve individuals with human immunodeficiency virus-1 infection
[30,36,37]. Consistent with the cases of human immunodeficiency
virus-1 infection, a few studies detected minor variants resistant to
NA in the plasma of treatment-naı ¨ve patients with chronic HBV
infection [20,21]. It remains unclear, however, whether these
minor drug-resistant mutations have clinical significance. Our
observation of the relative expansion of viral clones with the
M204VI mutation during entecavir therapy in some cases
indicates the possibility that preexisting minor mutants might
provide resistance against NA through the selection of dominant
mutant clones. Future studies with a larger cohort size are required
to clarify the clinical implications of the latently existing low-
abundant drug-resistant mutations.
The current ultra-deep parallel sequencing technology has
limitations in the analyses of viral quasispecies. First, because the
massively-parallel ultra-deep sequencing platform is based on a
multitude of short reads, it is difficult to evaluate the association
between nucleotide sites mapped to different genome regions in a
single viral clone. Indeed, potential mutational linkages between
the pre-C and reverse transcriptase regions were difficult to
elucidate due to the short read length of the shotgun sequencing
approach. Second, accurate analysis of highly polymorphic viral
clones by ultra-deep sequencing is also difficult because the
identification of mutations depends strongly on the mapping to the
reference genome sequences.
In conclusion, we demonstrated that the majority of patients
positive for anti-HBe and negative for HBeAg lacked the
predominant infection of the G1896A pre-C mutant in the
presence of NA treatment, suggesting that the G1896A pre-C
mutant have increased sensitivity to NA therapy compared with
w i l d - t y p eH B V .W ea l s or e v e a l e dt h a td r u g - r e s i s t a n tm u t a n t s
are widely present, even in the liver of treatment-naı ¨ve HBV-
infected patients, suggesting that the preexisting low-abundant
mutant clones might provide the opportunity to develop drug
resistance against NA through the selection of dominant
mutations. Further analyses utilizing both novel and conven-
tional sequencing technologies are necessary to understand the
significance and clinical relevance of the viral mutations in the
pathophysiology of various clinical settings in association with
HBV infection.
Table 5. The prevalence of M204VI mutation at YMDD site in patients before and after entecavir administration.
Entecavir treatment
Before After
Prevalence of the mutated clones Prevalence of the mutated clones Period of NA treatment
Serum #3 222/32,238 (0.7%) 2,284/23,791 (9.6%) 2w
Serum #2 401/34,041 (1.2%) 266/25,301 (1.1%) 24w
Serum #5 521/48,723 (1.1%) 245/25,521 (1.0%) 56w
Serum #8 748/65,573 (1.1%) 336/28,702 (1.2%) 48w
Serum #9 312/30,599 (1.0%) 169/14,172 (1.2%) 56w
Serum #1 9/22,843 (-) 2,839/34,162 (8.3%) 8w
Serum #7 26/65,564 (-) 923/66,458 (1.4%) 4w
Serum #12 91/65,616 (-) 258/27,958 (0.9%) 24w
Serum #13 11/23,209 (-) 206/64,747 (0.3%) 32w
Serum #4 3/7,923 (-) 39/65,575 (-) 12w
Serum #6 52/65,582 (-) 77/55,273 (-) 16w
Serum #10 38/22,522 (-) 8/21,053 (-) 8w
Serum #11 47/43,853 (-) 5/16,520 (-) 16w
Serum #14 42/42,784 (-) 40/36,668 (-) 12w
Mutation frequency (%): the ratio of total mutant clones to total aligned coverage at each nucleotide sites.
(-): mutant clones less than 0.3% among total clones at each nucleotide sites.
doi:10.1371/journal.pone.0035052.t005
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